via University of Virginia School of Medicine
A common antidepressant could offer the first treatment for the leading cause of blindness among people over 50, new research from the University of Virginia School of Medicine suggests.
UVA’s Bradley D. Gelfand and collaborators have found early evidence that the drug fluoxetine – marketed as Prozac – may be effective against atrophic (or “dry”) age-related macular degeneration, a condition that affects nearly 200 million people worldwide. The drug has shown promise in the scientists’ lab tests and animal models, and the researchers bolstered their results by examining two huge insurance databases encompassing more than 100 million Americans. That analysis concluded that patients taking fluoxetine for depression were less likely to develop atrophic macular degeneration.
Based on their findings, the researchers are urging clinical trials to test the drug in patients with AMD. If successful, they believe the drug could be administered either orally or via a long-lasting implant in the eye.
“These findings are an exciting example of the promise of drug repurposing – using existing medicines in new and unexpected ways,” Gelfand, of UVA’s Center for Advanced Vision Science, said. “Ultimately, the best way to test whether fluoxetine benefits macular degeneration is to run a prospective clinical trial.”
Fluoxetine and AMD
The researchers believe fluoxetine works against AMD by binding with a particular agent of the immune system known as an inflammasome. This inflammasome, NLRP3-ASC, triggers the breakdown of the pigmented layer of the eye’s retina.
After conducting extensive bench research, Gelfand and his team tested fluoxetine and eight other depression drugs in lab mice to see what effect, if any, the drugs would have in a model of AMD. Fluoxetine slowed the progression of the disease, but the others did not, the scientists found.
Encouraged by their findings, the researchers looked at fluoxetine use among patients over age 50 in two enormous insurance databases. People taking the drug had a “significantly” slower rate of developing dry AMD, the researchers report in a new scientific paper outlining their findings.
They note that their approach, combining bench research with big-data analysis, could potentially facilitate the repurposing of existing drugs for many conditions, speeding new treatments to patients.
“Traditional approaches to drug development can be expensive and time-consuming: On average, a new FDA-approved drug takes 10 to 12 years and costs $2.8 billion (present-day dollars) to develop,” the researchers wrote. “Our identification of the unrecognized therapeutic activity of an existing FDA-approved drug using big data mining, coupled with demonstrating its efficacy in a disease-relevant model, could greatly accelerate and reduce the cost of drug development.”
Gelfand was involved earlier this year in using a similar approach to determine that HIV drugs known as nucleoside reverse transcriptase inhibitors, or NRTIs, may be useful against dry macular degeneration as well.
“While we have had a great deal of success with the approach of using real-world patient data, we may have only begun to scratch the surface of finding new uses for old drugs,” said Gelfand, of UVA’s departments of Ophthalmology and Biomedical Engineering. “It is tempting to think about all the untapped therapeutic potential of medicines sitting on pharmacy shelves.”
Original Article: PROZAC PEGGED AS POTENTIAL FIRST TREATMENT FOR A LEADING CAUSE OF BLINDNESS
More from: University of Virginia School of Medicine
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Drug repurposing
- Existing Drug Could Offer New Hope For Long COVID Thanks To World-First Discovery
In a world first, scientists have repurposed an existing drug and shown it could help fix faulty proteins thought to be involved in long COVID. The drug, naltrexone, is typically used to treat ...
- First effective treatment found for spitting cobra snakebite
Scientists have discovered a new snakebite treatment to prevent the devastating tissue damage caused by African spitting cobra venom. Spitting cobra venom is incredibly potent and causes dermonecrosis ...
- The oral cancer drug that could treat diabetes: Study
The experiment, the results of which were published May 3 in Nature Communications, used a focal adhesion kinase-inhibiting drug that is being studied in cancer treatment. Researchers found that the ...
- Repurposed cancer drug to help replace insulin therapy for diabetes
A drug used for the treatment of pancreatic cancer can be repurposed to replace insulin therapy among people with diabetes, scientists have found.
- Repurposed Cancer Drug Could Show Promise for Diabetes
Researchers show that a FAK-inhibiting drug, which has been studied in cancer treatment, converted acinar cells into acinar-derived insulin-producing (ADIP) cells and helped regulate blood glucose in ...
Go deeper with Google Headlines on:
Drug repurposing
[google_news title=”” keyword=”drug repurposing” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]
Go deeper with Bing News on:
Fluoxetine and AMD
- AMD RDNA 4: Everything we know about the RX 8000 series
AMD’s RDNA 4 graphics cards (also referred to as the Radeon RX 8000 series) are already on the horizon, but they’re still a bit of a mystery. Fortunately, while AMD is still keeping quiet ...
- AMD: Too Late And Too Little In The AI Game
With the gaming segment still reporting elevated inventory channels and slower IoT/ automotive recovery in the embedded segment, we are uncertain about AMD's intermediate term prospects.
- AMD’s mixed earnings reveal a company with a lot to prove — and the goods to do it
CEO Lisa Su has taken the company from the doldrums to one of the most tracked and important players in the world when it comes to computing and technology. For most of its existence, AMD has ...
- Analysts revise AMD stock price targets after earnings shock
AMD ( AMD) , which is attempting to carve into market leader Nvidia's ( NVDA) 80% share of the market for artificial-intelligence-focused data-center chips, has seen demand for some of its traditional ...
- AMD Says MI300 Is Its ‘Fastest-Ramping Product,’ Teases New AI Chips ‘Later This Year’
In AMD’s first-quarter earnings call, CEO Lisa Su called the Instinct MI300 its ‘fastest-ramping product’ ever and teased future AI chips coming ‘later this year into 2025.’ ...
Go deeper with Google Headlines on:
Fluoxetine and AMD
[google_news title=”” keyword=”Fluoxetine and AMD” num_posts=”5″ blurb_length=”0″ show_thumb=”left”]